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SUMMARY
To better understand the cellular origin of breast cancer, we developed a mouse model that recapit-
ulates expression of the ETV6-NTRK3 (EN) fusion oncoprotein, the product of the t(12;15)(p13;q25)
translocation characteristic of human secretory breast carcinoma. Activation of EN expression in
mammary tissues byWap-Cre leads to fully penetrant, multifocal malignant breast cancer with short
latency. We provide genetic evidence that, in nulliparous Wap-Cre;EN females, committed alveolar
bipotent or CD61+ luminal progenitors are targets of tumorigenesis. Furthermore, EN transforms
these otherwise transient progenitors through activation of the AP1 complex. Given the increasing
relevance of chromosomal translocations in epithelial cancers, such mice serve as a paradigm for
the study of their genetic pathogenesis and cellular origins, and generation of preclinical models.INTRODUCTION
For most malignancies neither the initiating genetic event
nor the cell of origin is known. Cancers are heterogeneous
in composition and are organized in a hierarchy that
includes cells competent to recreate the tumor on trans-542 Cancer Cell 12, 542–558, December 2007 ª2007 Elsevier Iplantation, designated tumor initiating cells (T-ICs) or can-
cer stem cells, and other cells comprising the bulk tumor
mass (Reya et al., 2001). Following the first hit, whether
it occurs within a stem or more differentiated cell, second-
ary events of genetic or epigenetic nature contribute to
evolution of malignancy. Access to these early steps inSIGNIFICANCE
For the largest class of human tumors, those of epithelial origin, little is known about their initiating genetic hits or
cells of origin.Whether tissue stem cells ormore committed progenitors are targets for transformation is uncertain.
We developed a system in which epithelial tumorigenesis can be assessed from the initial event to frank malig-
nancy. In this breast cancer model based on chromosomal translocation, we show through genetic marking
that committed mammary progenitors, rather than mammary stem cells, are direct targets of transformation.
We show that activation of the AP1 complex represents a critical downstream event of the ETV6-NTRK3 translo-
cation. Further focus on this transcriptional complex as a target in human breast cancer is warranted.nc.
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provide a window into this phase of cancer development
but are likely to be relevant to human biology only so far
as the genetic events mirror those occurring in patients.
In considering these issues, we have sought to apply to
a cancer of epithelial origin principles that have proved
successful in the study of hematopoietic malignancies. For
leukemias and childhood sarcomas, chromosomal trans-
locations leading to the production of chimeric proteins
serve as initiating genetic events (Rowley, 2001). Although
some gene rearrangements associated with leukemia
are rare, study of these infrequent events has defined
transcription factors critical for normal differentiation and
pathways more generally perturbed in malignancy.
Until lately, the contribution of chromosomal rearrange-
ments to epithelial cancers has been viewed as minor. Re-
cently, chromosomal rearrangements involving the ETS
family transcription factors were identified in >50% cases
of human prostate cancer (Tomlins et al., 2005, 2006,
2007). Furthermore, an EML4-ALK fusion gene was iden-
tified in 6.7% of non-small-cell lung cancer cases (Soda
et al., 2007). These observations prompt reassessment
of conclusions regarding the involvement of chromosomal
rearrangements in epithelial cancer.
t(12;15)(p13;q25) is a unique recurrent chromosomal
translocation associated with cancer of all germ layers, in-
cluding human secretory breast carcinoma (SBC) (Tognon
et al., 2002), congenital fibrosarcoma (Knezevich et al.,
1998b), congenital mesoblastic nephroma (Knezevich
et al., 1998a; Rubin et al., 1998), and acute myelogenous
leukemia (Eguchi et al., 1999). It produces a fusion onco-
gene, ETV6-NTRK3 (EN), which encodes a chimeric pro-
tein made up of the oligomerization domain of ETV6
(also known as TEL, an ETS family transcription factor)
and the protein tyrosine kinase (PTK) domain of NTRK3
(also known as TRKC, a TRK family tyrosine kinase recep-
tor for neurotrophin-3). The consistent presence of this
translocation in human SBC provides strong genetic epi-
demiological support for its role in the initiation of breast
cancer (Tognon et al., 2002).
Breast cancer is representative of other epithelial malig-
nancies in its heterogeneity, both genetically and clinically
(Simpson et al., 2005). In part, phenotypic heterogeneity
may reflect diverse cellular origins of different subtypes
of breast cancer (Ince et al., 2007).
Here we report a murine model of human sporadic breast
cancer based on theEN translocation. We demonstrate that
two committed mammary progenitors in the normal mam-
mary developmental hierarchy serve as target cells of
breast cancer. In addition, by performing microarray analy-
sis, we reveal that EN-initiated transformation is mediated
largely through activation of the c-Jun/Fosl1 AP1 complex.
RESULTS
Generating the Etv6-NTRK3 Conditional
Knockin Allele
We generated a Cre-Lox EN knockin allele by introducing
the portion of human NTRK3 cDNA encoding the PTKCandomain (as found in SBC patients) into exon 6 of the mouse
Etv6 locus (Figure 1A). We rendered this fusion allele con-
ditional by insertion of a ‘‘floxed’’ transcriptional terminator
sequence (‘‘stopper’’ [Mao et al., 1999]; Figure 1A] into
the intron upstream of the knockin NTRK3 cDNA. The
resulting allele, once activated by Cre-mediated excision
of the floxed ‘‘stopper,’’ produces a mouse Etv6-human
NTRK3 hybrid protein, which transforms NIH 3T3 cells
(data not shown). Therefore, the EN knockin allele
recapitulates the chimeric protein seen in patients.
We identified correctly targeted ES cell clones using
Southern blot (Figure 1B). By RT-PCR, we found EN ES
cells without excision exhibited slightly leaky expression
of the EN allele, but removal of the ‘‘stopper’’ greatly in-
creased its expression (Figure 1C). At the protein level
(Figure 1D), no EN fusion protein was detected in unex-
cised ES cells. However, its expression was readily visible
from ‘‘stopper’’-excised ES cells. Thus, the EN conditional
knockin allele functions as designed.
The Endogenous Etv6 Locus Is Active inMammary
Epithelial Cells
Because EN is under the control of the endogenous Etv6
promoter, we first examined where Etv6 is normally
expressed in mammary glands (MGs) using a mouse
strain we generated (TEA175) that carries an Etv6 locus
having a b-Geo cassette inserted between its exons 2
and 3 and serves as a reporter for its expression.
Upon staining MGs from TEA175 heterozygous females
for lacZ activity, we found that Etv6 is expressed in both
ductal and alveolar mammary epithelial cells (MECs) (Fig-
ure S1A in the Supplemental Data available with this article
online). In addition, flow cytometry analysis revealed
lacZ+ cells in all four major MEC subpopulations defined
previously (Stingl et al., 2006) (Figure S1B).
Activation of EN in Mammary Glands byWap-Cre
Leads to Mammary Tumors with Complete
Penetrance
Without Cre-mediated activation of EN, heterozygotes
were indistinguishable from their wild-type (WT) litter-
mates. Some EN heterozygous females (and very rarely,
males) developed mammary tumors at advanced ages
(>1 year), possibly due to the leakiness of the ‘‘stopper’’
and low-level EN expression (Figure 1C).
To activate EN expression in MGs, we initially planned
to use two commonly used MG-specific Cre mouse lines,
MMTV-Cre and Wap-Cre (Wagner et al., 1997). Unfortu-
nately, use of MMTV-Cre led to a lethal myeloproliferative
disease within several weeks after birth, apparently due to
expression of MMTV-Cre in the hematopoietic system
(data not shown).
The more restricted expression of the endogenous
Wap gene as well as that of the Wap-Cre transgene
(Boulanger et al., 2005; Kordon et al., 1995; Robinson
et al., 1995, 1996; Wagner et al., 2002) afforded an ap-
proach for activation of EN in MGs without accompany-
ing effects in other tissues. In maturing and mature nul-
liparous female mice, Wap+ cells are present onlycer Cell 12, 542–558, December 2007 ª2007 Elsevier Inc. 543
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ETV6-NTRK3 Transforms Mammary Progenitors via AP1Figure 1. Generating the Etv6-NTRK3
Conditional Knockin Allele
(A) Schematic diagrams of the endogenous WT
Etv6 allele, the Etv6-NTRK3 (EN) conditional
knockin allele, the activated EN allele upon
Cre-mediated excision of the floxed Neo-
stopper cassette (ST, stopper), and the EN fu-
sion protein produced from the activated EN
allele. The 50 and 30 probes for Southern blot
are shown. X, XhoI; S, SpeI; A, ApaI; E, EcoRV;
N, NotI; VI, VII, VIII, exon 6, 7, and 8 of Etv6;
p(A), poly(A) signal; SAM(PNT), sterile alpha
motif/pointed domain; PTK, protein tyrosine
kinase domain.
(B) Southern blot screen and confirmation of
correctly targeted ES cell clones. The 50 probe
recognizes a 16.1 kb XhoI fragment from the
WT Etv6 allele, a 13.3 kb XhoI fragment (due
to incomplete digestion of NotI) and an 11 kb
XhoI-NotI fragment (complete digestion) from
the EN knockin allele. The 30 probe recognizes
a 7.6 kb EcoRV fragment from the WT allele,
and a 12.2 kb EcoRV fragment from the EN
allele.
(C) RT-PCR analysis showing greatly elevated
expression of the EN fusion transcript from
the ‘‘stopper’’-excised ES cells (EN28.12).
Note that EN has slightly leaky expression in
the parental EN28 ES cells (without excision
of the ‘‘stopper’’).
(D) Western blot showing detection of the EN
fusion protein (tyrosine phosphorylated dou-
blet) from the ‘‘stopper’’-excised ES cells
(EN28.12, EN28.19), but not from the parental
EN28 ES cells. EN-3T3 cells were used as the
positive control.transiently as a minor subset at estrus. Wap expression
is greatly elevated in differentiating MECs during late
pregnancy and lactation and then turned down following
involution.
Based on the expression pattern ofWap, we initially pre-
dicted that Wap-Cre;EN (hereafter, WCEN) female mice
might require rounds of pregnancies in order to express
sufficient Cre to activate EN. Unexpectedly, however, all
nulliparous WCEN females develop multifocal mammary
tumors as early as 4 months of age (Figure 2A), with pre-
ceding lobuloalveolar hyperplasia (Figure 2B). Parous
WCEN females develop similar multifocal mammary tu-
mors with antecedent alveolar hyperplasia, and with no
significant differences in tumor latency and histology.
Some aged WCEN males also develop mammary tumors
(Figure 2A and data not shown).
To confirm that mammary tumors in WCEN animals
resulted from activation of EN expression, we performed
PCR analysis on genomic DNA prepared from tumors
and other organs of WCEN animals and found that the544 Cancer Cell 12, 542–558, December 2007 ª2007 Elsevier I‘‘stopper’’ in the EN allele was excised only in tumor cells
(Figure 2C). Consistent with this, we also detected EN
protein in tumor tissues by western blot (Figure 2D). Previ-
ous studies demonstrated that expression of the EN
fusion protein in 3T3 cells led to constitutive phosphoryla-
tion of Mek1/2 and Akt as well as to a constitutive high-
level expression of cyclin D1/2 (Tognon et al., 2001). These
features also characterized EN-initiated mammary tumors
(hereafter, EN tumors) (Figure 2D).
EN tumors were heterogeneous both with respect to
morphology and rate of tumor progression (Figures 2Ea–
2Ed and data not shown). Most EN tumors were highly
invasive and transplantable upon subcutaneous injection
into immunodeficient mice. The rate of tumor regrowth
following transplantation correlated with the apparent
rate of progression of the corresponding primary tumor.
Due to the relatively short latency of these tumors, most
WCEN mice failed to show signs of metastasis. On occa-
sion, metastases to lymph node and lung were observed
(Figures 2Ef and 2Eh).nc.
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ETV6-NTRK3 Transforms Mammary Progenitors via AP1Figure 2. Wap-Cre;EN Mice Develop Mammary Tumors with Antecedent Alveolar Hyperplasia
(A) Tumor-free curves.
(B) Mammary glands (MGs) ofWCEN females (Ba and Bc) exhibit extensive lobuloalveolar hyperplasia compared to WT (Bb and Bd). (Ba and Bb) MG
whole mounts stained with hematoxylin. (Bc and Bd) Hematoxylin & eosin (H&E)-stained MG sections (scale bars, 200 mm). Red arrows: alveolar
hyperplasia. Blue arrows: dilated ducts and accumulation of secretions within ducts.
(C) PCR analysis on genomic DNA shows excision of the Neo-stopper cassette only in the tumor. Locations of PCR primers (1–4) are indicated.
(D) Western blot analysis of the WCEN tumor. EN-3T3 cells were used as the positive control. IP/western confirms EN expression in both the tumor
and EN-3T3 cells.
(E) Histology (H&E-stained sections; scale bars, 100 mm) of mammary tumors developed in WCEN mice. (Ec) shows squamous metaplasia, (Ee) and
(Ef) were from a nulliparous female, (Ee) shows a primary mammary tumor, and (Ef) shows metastasis in a lymph node; (Eg) and (Eh) were from a male,
(Eg) shows a primary mammary tumor, and (Eh) shows metastasis in the lung.Cancer Cell 12, 542–558, December 2007 ª2007 Elsevier Inc. 545
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ETV6-NTRK3 Transforms Mammary Progenitors via AP1Figure 3. Target Cells of Mammary Tumors Developed inWap-Cre;EN Virgins Are Transient Mammary Progenitors, Rather Than
MaSCs
(A) Schematic diagram of the lacZ-marking experiment. Normal WCLZ virgin MGs contain a transient wave of lacZ+ MECs. In WCENLZ mutant MGs,
the transient lacZ+ MECs appear to be rescued from death and lead to lacZ+ alveolar hyperplasia and eventually lacZ+ mammary tumors.
(B–E) (B) and (D) show whole mounts of WCENLZ MG and tumor stained for lacZ activity. (C) and (E) are lacZ-stained tissue sections counterstained
with nuclear fast red. Note that, in (B) and (C), lacZ+ cells are mainly restricted to the alveolar compartment. Scale bars, 100 mm.
(F) Flow cytometry analysis of a WT MG, aWCEN hyperplastic MG, and aWCEN tumor. The profiles shown here have already been gated for lineage-
negative (Lin) cells. Percentages of positive cells are from a representative experiment.The Transient Wap+ Cells in Nulliparous Wap-
Cre;EN Mammary Glands Are Target Cells of EN
In nulliparous female mice, Wap is activated in a small,
transient population of MECs during estrus (Kordon
et al., 1995; Robinson et al., 1995, 1996). Further studies
in Wap-Cre;Rosa-Stop-lacZ (hereafter, WCLZ) females
showed that Wap-Cre+ (thus also lacZ+) MECs failed to
persist in WCLZ mice during diestrus. Since lacZ+ cells
do not accumulate in nulliparous WCLZ mice, it is inferred
that the MECs in which Wap is first activated do not prolif-
erate extensively and possibly die through apoptosis (Bou-
langer et al., 2005; Henry et al., 2004; Wagner et al., 2002).
In addition, one can infer that Wap-Cre+ cells are not
equivalent to mammary stem cells (MaSCs) in virgin mice.
Since WCEN nulliparous females develop multifocal
mammary tumors with 100% penetrance and the transient
Wap+ MECs are likely the only cells in virgins that express
Cre and, therefore, activate EN expression, we conjec-
tured that these cells might be direct targets of EN trans-
formation (Figure 3A). To test this hypothesis, we interbred
a Rosa-Stop-lacZ reporter (Mao et al., 1999) into the
WCEN background and generated Wap-Cre;EN;Rosa-
Stop-lacZ (hereafter, WCENLZ) females. We predicted
the presence of lacZ+ hyperplastic MECs in MGs and
subsequent development of lacZ+ mammary tumors
(Figure 3A). Indeed, lacZ staining was primarily restricted546 Cancer Cell 12, 542–558, December 2007 ª2007 Elsevier Ito hyperplastic alveolar cells in hyperplastic MGs (Figures
3B and 3C). Moreover, lacZ+ cells were confined to tumor
epithelial cells in mammary tumors (Figures 3D and 3E).
Thus, genetic marking suggests that activation of EN by
Cre rescues an otherwise transient subpopulation of
MECs and maintains them and their progeny for subse-
quent steps in progression to frank malignancy. Further-
more, we reasoned that T-ICs in WCENLZ tumors should
also be marked by lacZ. To test this, we transplanted
tumor cells into immunodeficient mice after limited dilu-
tions. Without fractionation, typically 104–105 EN tumor
cells were needed to form new tumors in Rag2/ mice.
In contrast, only 103–104 (sometimes even as low as
600) sorted lacZ+ tumor cells were sufficient to initiate
new tumors in Rag2/ hosts. This suggests that T-ICs,
evolved from EN target cells, are enriched in the popula-
tion of lacZ-marked EN tumor cells.
Wap-Cre;EN Hyperplastic Mammary Glands
and Tumors Accumulate CD24+Sca-1+ Cells
To characterize further the nature of the EN target cells,
we examined surface markers that have previously been
used to fractionate mammary tissues into enriched stem
or progenitor populations (Shackleton et al., 2006; Stingl
et al., 2006; Welm et al., 2002). By flow cytometry analysis,
most EN tumor cells were CD24+Sca-1+ (Figure 3F).nc.
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Cre;EN Tumors Characterized by Immu-
nostaining and Microarray Analysis
(A) EN type 1 (bipotent: [Aa], [Ac], and [Ae]) and
type 2 (CD61+: [Ab], [Ad], and [Af]) tumors
based on K5/K8 (Aa and Ab), K14/K8 (Ac and
Ad), and CD61/CD29 (Ae and Af) staining
patterns. Scale bars, 50 mm.
(B) Flow cytometry analysis showing that
K8+K14+ cells in EN type 2 tumors are CD61+.
In normal MGs, almost all CD61+ MECs (gates
R1–R3) are K14+. Gate R4 represents nonepi-
thelial cells in MGs.
(C) Hierarchical cluster analysis of 12 WCEN
tumors (type 1 and 2, blue lines) together with
122 samples from other murine models of
breast cancer and normal MGs. MMTV-Wnt1
tumors (clusters I and II) are highlighted by
yellow lines. MMTV-Neu and MMTV-PyVT
tumors are highlighted by red lines. Heat
maps of three representative gene clusters
(K5, K14, and Xbp1) are shown (heat maps
showing all genes in the intrinsic gene list are
shown in Figure S5). Gene names for each
cluster are listed in Table S8. In the heat map,
red, black, and green represent above aver-
age, average, and below average levels of ex-
pression, respectively. Gray indicates no data
recorded.Moreover, MGs from mature nulliparous WCEN females
contained a greater number of CD24+Sca-1+ cells than
WT controls even before they developed tumors (Fig-
ure 3F). In contrast, the MaSC-enriched LinCD29hiCD24+
(Shackleton et al., 2006; and the similar LinCD49fhiCD24+
[Stingl et al., 2006]) subpopulation is not altered in WCEN
hyperplastic MGs (Figure 3F). These data argue that mam-
mary tumors inWCENmice are unlikely to arise from trans-
formation of MaSCs; instead, they may be derived from
committed CD24+Sca-1+ mammary progenitors.
Wap-Cre;EN Mammary Tumors Are Derived
from Committed Alveolar Progenitors
In analogy to the hematopoietic system, a developmental
hierarchy for MECs, including MaSCs, bipotent ductal or
alveolar progenitors, single lineage-restricted progenitors,
and mature luminal or myoepithelial cells, has been pro-
posed (Asselin-Labat et al., 2007; Hennighausen and
Robinson, 2005). To position target cells of EN in this hier-
archy, we performed immunostaining for the luminal
epithelial cell marker keratin 8 (K8), basal/myoepithelialCancell markers keratin 5 (K5) and 14 (K14), p63, and
a-smooth muscle actin (SMA), as well as the mammary
progenitor marker keratin 6 (K6), and estrogen receptor
(ERa) (Figure 4A and Figure S2). Overall, we have identi-
fied two broad tumor types in WCEN mice. The majority
of EN tumors (type 1, 90%) exhibit relatively well-
differentiated glandular structures and contain K8+ luminal
epithelial cells surrounded by basal/myoepithelial cells
that are positive for K5, K14, p63, and sometimes, SMA.
Occasionally there are K5+K14+p63+SMA+or basal/my-
oepithelial cells ‘‘leaking’’ into the region of luminal
epithelial cells (Figure 4A and Figures S2A and S2D). In
the most extreme case, some type 1 tumors (type 1a, or
regions within these tumors) contain a large number of
K5+K14+p63+SMA+or basal/myoepithelial cells inter-
mixed with a smaller number of K8+ luminal epithelial cells
in a less organized manner (Figure S2A). A second class of
EN tumors (type 2, 10%) exhibits no K5+K14+p63+
basal/myoepithelial cells but contains predominantly K8+
luminal epithelial cells. Interestingly, a large number of
K8+ cells in these tumors are also K14+ (but K5)cer Cell 12, 542–558, December 2007 ª2007 Elsevier Inc. 547
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lack these abnormal K8+K14+ cells. However, some type
1a tumors do contain a small number of K8+K14+ cells (Fig-
ure S2A). In addition, we also identified an additional sub-
type of type 1 tumors (type 1b) that exhibit glandular struc-
tures, with K8+ luminal epithelial cells surrounded by
K5+K14+ basal/myoepithelial cells. However, many of
these K8+ luminal cells are also K14+ (Figure S2A), thus
representing tumors with features of both types (1 and 2).
A summary of the staining properties of cells in the different
types of EN tumors is provided in Figure S2B. The majority
of type 1 tumors contain K6-expressing cells, whereas
very few or no K6+ cells are present in type 2 tumors
(Figure S2C). However, tumors of both types express
Sca-1 (data not shown) and are ERa+ (Figure S2E). Inter-
estingly, upon careful examination by immunofluores-
cence colocalization, we observed a significant number
of ERa+p63+ and ERa+SMA+ cells, in addition to the
ERa+p63SMA luminal epithelial cells (Figure S2E).
Recently, CD61 (integrin b3) has been shown to mark
the luminal progenitors in normal MGs (Asselin-Labat
et al., 2007). Interestingly, we find that all type 2 tumors
abundantly express CD61, whereas most of the type 1 tu-
mors contain much fewer CD61+ cells (Figures 4Ae and
4Af), with the exception of type 1b tumors. Microarray ex-
pression profiling confirms that type 2 tumors express the
highest levels of CD61, followed by type 1b, and then the
remaining type 1 tumors (data not shown). Since type 2 tu-
mors exhibit ‘‘luminal’’ appearance and are characterized
by large numbers of K8+K14+ cells, we asked whether
these double-positive cells might represent blocked
CD61+ progenitors. In fact, flow cytometry analysis re-
vealed that almost all K8+K14+ cells in these tumors are
CD61+ (Figure 4B). In normal MGs, the majority of CD61+
cells are K8K14+ cells, whereas K8+K14 luminal cells
are CD61 (Figure 4B). We also detected a small popula-
tion of K8+K14+ cells, a significant number of which also
express CD61 (Figure 4B). These data suggest that CD61+
luminal progenitors are K14-expressing cells, and the ab-
normal K8+K14+ cells in EN type 2/type 1b tumors proba-
bly represent CD61+ luminal progenitors blocked in differ-
entiation toward K8+K14 mature luminal epithelial cells.
In type 1 EN tumors, the K5+ basal/myoepithelial cells,
in addition to the K8+ luminal cells, are part of the tumor
epithelial cell population. When we compared microarray
expression profiles generated from sorted tumor epithelial
cells based on the above-described lacZ marker in
WCENLZ females to those from unfractionated tumors,
we observed slight enrichment (rather than loss) of both
the K5 basal gene cluster and the K14 cluster (as defined
in Figure 4C, discussed below) in sorted lacZ+ tumor cells,
as determined by gene set enrichment assay (GSEA) (data
not shown) (Subramanian et al., 2005). This confirms that
basal/myoepithelial cells in EN tumors are part of the tu-
mor epithelial cells, not normal cells recruited to tumors.
Due to the presence of mixed cell types in type 1 EN
tumors, the cells from which tumors originate could
be MaSCs, bipotent progenitors, or multiple lineage-
committed progenitors. Since the above-described ge-548 Cancer Cell 12, 542–558, December 2007 ª2007 Elsevier Inetic marking experiment and flow cytometry analysis
(Figure 3) both rule out MaSCs as targets of EN, we next
asked whether tumors are derived from distinct lineage-
restricted progenitors (i.e., multiclonal), or from bipotent
progenitors (i.e., clonal).
We used aWap-rtTA-Cre transgenic line that expressed
Cre in Wap+ cells in the presence of doxycycline (Utomo
et al., 1999). We generated animals with both Wap-rtTA-
Cre and EN, some of which also carried a conditional
luciferase reporter at the Rosa26 locus (Rosa-Stop-Luc,
similar to the above-described Rosa-Stop-lacZ reporter
[Safran et al., 2003]). Unexpectedly, we found that the
Wap-rtTA-Cre transgene exhibits leaky Cre expression,
and Wap-rtTA-Cre;EN nulliparous females developed
mammary tumors without doxycycline. These tumors
also featured cells of both luminal and basal/myoepithelial
lineages (Figure S3A). Since Cre should be expressed at
a low level without doxycycline, sometimes it might excise
the ‘‘stopper’’ at the EN allele but not that at the Rosa-
Stop-Luc allele within the same cell. If a tumor arose
from a cell with this genotype, tumor epithelial cells would
all inherit the recombined EN allele and the unmodified
Rosa-Stop-Luc allele. Indeed, in a tumor arising in a
Wap-rtTA-Cre;EN;Rosa-Stop-Luc nulliparous female, we
detected excision only at the EN locus, and not at the
Rosa-Stop-Luc locus (Figure S3B). Since it is highly un-
likely for multiple lineage-restricted progenitors to obtain
the same partial excision pattern (as described above)
and then give rise to a tumor with this pattern, our obser-
vation supports the clonal origin of type 1 EN tumors from
bipotent progenitors.
Furthermore, microarray data reveal that, compared to
normal MGs, both type 1 and 2 EN tumors express high
levels of the alveolar cell marker k-casein, but low levels
of the ductal cell marker NKCC1 (also known as ‘‘solute
carrier family 12, member 2’’) (Figure S4A), suggesting
an alveolar cellular origin. In contrast,MMTV-Wnt1 tumors
do not express (or express low levels of) k-casein but ex-
press NKCC1 in a fraction of tumor cells, consistent with
MaSCs as potential target cells to give rise to both ductal
and/or alveolar cells (Li and Rosen, 2005) (Figure S4B).
Taken together, we conclude that target cells of mammary
tumors arising in WCEN females are either committed
bipotent alveolar progenitors (type 1) or luminal alveolar
progenitors (type 2). These progenitors are within the tran-
sient Wap+ cells in nulliparous females.
Wap-Cre;EN Mammary Tumors Express Both
Luminal and Basal Gene Clusters
We compared EN tumors to other murine breast cancer
models by microarray expression profiling, using hierar-
chical clustering based on an intrinsic gene list developed
for murine models of breast cancer (Herschkowitz et al.,
2007). As shown in Figure 4C and Figure S5, in general,
compared to other murine models, EN tumors are rela-
tively homogeneous and cluster together. However, the
3 type 2 tumors (D14T1, D14T2, and C117T1) form their
own subcluster and are separated from the type 1 tumors.
In contrast, tumors from parous (CR115, CR90-1, D14T1,nc.
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males are mixed together and do not form distinct sub-
clusters. These data suggest that the initiating oncogenic
event and cellular origin, but not the reproductive history,
are more important in determining phenotypes of EN
tumors.
All type 1 EN tumors express 3 gene clusters, including
a K5 basal gene cluster, a strong K14 cluster, and a strong
Xbp1 luminal gene cluster, similar to MMTV-Wnt1 tumors
(Figure 4C). Type 2 EN tumors express the K14 and Xbp1
clusters, but not the K5 cluster. In contrast, tumors from
both MMTV-Neu and MMTV-PyVT mice only express the
Xbp1 luminal cluster (Figure 4C). Of note, MMTV-Wnt1
tumors are more heterogeneous than EN tumors and they
can also be divided into two major subclusters. One con-
tains K5 and K14 clusters, but not the Xbp1 luminal cluster
(Figure 4C, cluster I). The other contains the K5 basal clus-
ter and the Xbp1 luminal cluster (though expressed at
slightly lower levels), but not the K14 cluster (Figure 4C,
cluster II). These differences may be due in part to their
different cells of origin, with MaSCs as more likely targets
of MMTV-Wnt1 tumors, and committed progenitors as
targets of EN.
An AP1 Signature Associated with EN-Mediated
Mammary Tumorigenesis
To understand the mechanism of EN-mediated mammary
tumorigenesis, we first performed GSEA on microarray
expression profiles from unsorted EN tumors compared
to those from normal MGs, using curated gene sets (c2
collection) for metabolic and signaling pathways from
the GSEA molecular signature database website (http://
www.broad.mit.edu/gsea/msigdb/msigdb_index.html).
Unexpectedly, this analysis only revealed pathways that
seem to be common for tumor cells in general (e.g., re-
flecting increased metabolic activities and proliferation;
Table S1). Two possibilities may account for this result.
First, pathways that are active in both normal MGs and tu-
mors may not be revealed by this assay. Second, noncan-
cerous cells in these tumors could introduce significant
‘‘noise’’ in unsorted tumor samples.
In our WCENLZ animals, tumor epithelial cells are la-
beled by lacZ (Figures 3B–3E). Thus, we have the oppor-
tunity to mark tumor epithelial cells and separate them
from stromal cells. In addition, target cells of EN in
WCLZ virgin females as well as premalignant, hyperplastic
MECs in WCENLZ females are also marked by lacZ, thus
providing an opportunity to isolate these cells for analysis.
We generated microarray expression profiles for several
lacZ-sorted samples from either WCENLZ hyperplastic
MGs that had not developed visible tumors, or mammary
tumors that arose in WCENLZ females. We then com-
pared sorted tumor cells to sorted hyperplastic MECs by
GSEA using the above-described c2 gene sets, in an at-
tempt to identify pathways upregulated during tumor pro-
gression. The top gene sets enriched in sorted tumor cells
derived from this comparison are more informative than
the comparison using unsorted tumors (Table S2, com-
pare to Table S1). Pathways related to the hypoxia re-Cancsponse in tumors, WNT signaling, TRK/NGF signaling,
TGFb signaling, and genes regulated by MYC are evident.
To further validate the effectiveness of this approach, we
also compared unsorted tumors to sorted hyperplastic
MECs (thus both comparisons have the same baseline).
The top gene sets enriched in unsorted tumors revealed
from this analysis are very similar to those compared to
normal MGs (Table S3, compare to Table S1), suggesting
that GSEA using sorted tumor cells may reveal pathways
with better specificity than using unsorted tumors.
We next compared sorted tumor cells to unsorted tu-
mors by GSEA using c2 gene sets. We reasoned that
genes/pathways upregulated specifically in tumor epithe-
lial cells would be further enriched in this comparison.
This would also potentially reveal an overall EN ‘‘signature’’
in the tumor epithelial cell compartment composed of
pathways upregulated during the initial transformation, or
tumor progression, or both. Among gene sets enriched in
sorted tumor cells, we observed pathways related to genes
regulated by C/EBP, IL6 response, HOXA5 targets, WNT
signaling, JNK signaling, and TGFb signaling (Table S4).
To determine what portion of the EN tumor signature
is acquired during tumor initiation, ideally we would need
to sort normal target cells of EN and compare their expres-
sion profiles to those from sorted hyperplastic MECs.
Unfortunately, lacZ staining of mammary tissues by
FDG dye yields a significant amount of background stain-
ing (1%–3% even for lacZ tissues). This background
staining does not cause difficulty when sorting lacZ+ hy-
perplastic MECs or tumor cells, which typically constitute
10%–40% of total cells, but prohibits sorting the small
population of transient EN target cells (0.8%–4% as esti-
mated by Wagner et al. [Wagner and Smith, 2005]) with
sufficient confidence. To overcome this technical limita-
tion, we turned to an in vitro model of EN signaling. Be-
cause EN is a unique oncoprotein in that it transforms cells
of all germ layers, we reasoned that the mechanism of EN-
mediated transformation might be conserved in different
cell types. EN-mediated signaling in NIH 3T3 cells has
been studied previously (Tognon et al., 2001; Wai et al.,
2000), many of which were also observed in EN tumors
(Figure 2D). Thus, we generated microarray expression
profiles from EN-transduced 3T3 cells (EN-3T3) and com-
pared them to those of untransformed 3T3 cells. By per-
forming GSEA using c2 gene sets, we identified several
common gene sets that are enriched in both EN-3T3 cells
and sorted EN tumor cells, including 2 IL6 pathways,
‘‘WNT_TARGETS,’’ ‘‘CHEN_HOXA5_TARGETS_UP,’’ and
‘‘TGF_BETA_SIGNALING_PATHWAY’’ (Table S5, com-
pare to Table S4).
Since ‘‘WNT_TARGETS’’ arose among the top-enriched
gene sets in all three analyses, we next focused on this
gene set. By comparing the core enrichment genes from
all three analyses, we observed striking similarity between
sorted tumor cells (compared to unsorted tumors) and EN-
3T3 cells (compared to control 3T3 cells) (Figures S6A and
S6B), including genes such as JUN, FOSL1, PLAUR, and
CD44. JUN and FOSL1 (also known as FRA1) encode
components of the AP1 complex and are target genes ofer Cell 12, 542–558, December 2007 ª2007 Elsevier Inc. 549
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ETV6-NTRK3 Transforms Mammary Progenitors via AP1Figure 5. Enrichment of c-Jun/Fosl1 and AP1 Targets in EN-Transformed Cells
(A–C) GSEAs show enrichment of c-Jun/Fosl1 and AP1 target genes in sorted EN tumor cells compared to unsorted tumors (A) and sorted hyper-
plastic cells (C), and in EN-3T3 cells (B). Genes expressed at higher levels in both sorted tumors and EN-3T3 cells are highlighted with green lines.
Genes expressed at higher levels in both sorted hyperplastic MECs and EN-3T3 cells are indicated by red arrows.b-catenin in human colorectal carcinomas. PLAUR en-
codes uPAR, and its transcription is activated through
AP1 (Mann et al., 1999). In addition, CD44 can also be up-
regulated by AP1 activity (Lamb et al., 1997). Thus, this
four-gene set appears to represent an AP1 signature.
Consistent with the above data, we also observed en-
richment of all gene sets containing genes with the AP1-
binding motif in the c3 collection of GSEA database in550 Cancer Cell 12, 542–558, December 2007 ª2007 Elsevier Insorted tumor cells and EN-3T3 cells (Table S6). More di-
rectly, we manually compiled a gene set for AP1 target
genes based on published literature (plus JUN and FOSL1)
(Eferl and Wagner, 2003) and observed its significant en-
richment in both sorted EN tumor cells and EN-3T3 cells
(Figures 5A and 5B). In addition to the above-described
four-gene set, we identified additional AP1 target genes
that are upregulated in both comparisons, includingc.
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ETV6-NTRK3 Transforms Mammary Progenitors via AP1Figure 6. Upregulation and Activation of the c-Jun/Fosl1 AP1 Complex Is Associated with EN-Mediated Transformation
(A) AP1 EMSAs on nuclear lysates from control, EN, or EN kinase-dead (KD) transduced 3T3 cells. Incubation with a specific unlabeled competitor
blocks band shift (lane 3). EN-3T3 nuclear lysates produced a significantly larger band shift compared to control or EN KD-3T3 lysates (compare lane
5 to lanes 2 and 6).
(B) Antibodies specific to Fosl1, Fosl2, and c-Jun band-shifted or destroyed the AP1 band shift produced by EN nuclear extracts, whereas antibodies
to c-Fos and Sp1 had no effect.
(C) Western blot analysis performed on lysates from serum-starved control (MSCVp), kinase-dead EN (EN-KD), and EN 3T3 cells. EN cells possessed
a tyrosine phosphorylated oncoprotein doublet and elevated levels of phosphorylated Akt, MEK, and c-Jun (ser 63 and 73) as well as elevated levels of
Fosl1, total c-Jun, and cyclin D1/2. Loading control: Grb2.
(D) Immunofluorescence (Da–Dc and Dg–Di) and immunohistochemical (Dd–Df and Dj–Dl) staining of WT MGs (Da, Dd, Dg, and Dj), EN hyperplastic
MGs (Db, De, Dh, and Dk), and EN mammary tumors (Dc, Df, Di, and Dl) with antibodies against Fosl1 (Da–Dc), phosphorylated c-Jun at Ser63 (Dd–Df)
and at Ser73 (Dg–Di), and total c-Jun (Dj–Dl). WT MGs in (Da), (Dd), and (Dj) were from nulliparous female mice. WT MG in (Dg) was from a lactating
female. Scale bars, 50 mm.
(E) Immunostaining of three SBC cases confirms the presence/activation of the c-JUN/FOSL1 AP1 complex. Scale bars, 50 mm.HBEGF (heparin-binding EGF-like growth factor),
BCL2L11 (BIM), CDKN1A (p21), and CDKN2A (p16).
p16INK4A and p21WAF1 typically function as tumor suppres-
sors. However, both may also act as oncogenes. In fact,
overexpression of p16 is found in breast cancer cases
with a more malignant phenotype (Milde-Langosch et al.,
2001). Of note, we did not observe significant enrichment
of this AP1 signature in sorted EN tumor cells compared to
sorted EN hyperplastic MECs (Figure 5C and Figure S6C),Cansuggesting that at least part of this signature might have
already been acquired in hyperplastic MECs during the
initial stage of EN transformation.
To confirm involvement of the c-Jun/Fosl1 AP1 complex
in EN-mediated transformation, we performed electro-
phoretic mobility shift assays (EMSAs) on nuclear lysates
from 3T3 cells and observed a significantly larger and spe-
cific band shift created by AP1 complex formation in EN-
3T3 cells (Figure 6A). This AP1 complex was composed ofcer Cell 12, 542–558, December 2007 ª2007 Elsevier Inc. 551
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ETV6-NTRK3 Transforms Mammary Progenitors via AP1Figure 7. Expression of a Dominant-Negative c-Jun Blocks EN-Mediated Transformation
(A) Expression of dominant-negative (DN) c-Jun in EN-expressing cells confirmed by western blot analysis. Loading control: total Akt.
(B and C) DN c-Jun expression reverts EN-mediated morphological transformation ([B], scale bars, 50 mm) and soft agar colony formation ([C], error
bars = mean ± SD) in 3T3 cells.
(D) Western blot analysis of serum-starved control cells (MSCVp) and EN cells (alone, coexpressing DN c-Jun, or treated with either MEK inhibitor
U0126 or PI3K inhibitor LY294002 [LY] [25 mM]). Both U0126 treatment and coexpression of DN c-Jun had a significant effect upon cyclin D1/2 levels
in EN cells. Loading control: total Akt.
(E) Effects of EN and DN c-Jun expression on EpH4 cell growth after 4 days in 3D Matrigel cultures. Scale bars, 500 mm.
(F) Effects of EN and DN c-Jun expression on human MCF10A cell growth in 3D Matrigel cultures. Scale bars, 1000 mm.
(G) Tumor growth curves of luciferase expressing cells injected subcutaneously into nude mice. ROI, regions of interest values in photons/s/cm2/sr.
(H) Comparison of bioluminescent images of mice at day 14 and day 22.
(I) Top panel shows Gfp+ cells in an empty-vector transduced EN tumor developed in theRag2/ host. Lower panel shows three distinct populations
of Gfp+ cells (R1–R3 express high, medium, and low levels of Gfp, respectively) in a DN c-Jun transduced EN tumor developed in the Rag2/ host.
(J) PCR genotyping (using a forward primer in the DN c-Jun and a reverse primer in the PGK promoter of the viral vector) confirms integration of DN
c-Jun viruses in all three populations (R1–R3) of the DN c-Jun/EN tumor. This primer set does not detect the control viruses (vector only).552 Cancer Cell 12, 542–558, December 2007 ª2007 Elsevier Inc.
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ETV6-NTRK3 Transforms Mammary Progenitors via AP1c-Jun and Fosl1 or Fosl2 (Figure 6B). Western blot analy-
sis confirmed significantly elevated levels of total c-Jun,
phosphorylated c-Jun, and Fosl1 only in EN-3T3 cells
(Figure 6C), suggesting that c-Jun/Fosl1 is indeed the
major AP1 complex formed upon EN-mediated transfor-
mation.
To validate upregulation and activation of the c-Jun/
Fosl1 complex in EN tumors, we performed immunostain-
ing using antibodies against Fosl1, phosphorylated c-Jun,
and total c-Jun. In WT MGs, Fosl1 is mainly localized in cy-
toplasm (Figure 6Da). In EN hyperplastic MECs and tumor
cells, the overall intensity of Fosl1 staining is increased,
and more importantly, significant Fosl1 nuclear staining
is detected (Figures 6Db and 6Dc). In addition, upregula-
tion and phosphorylation of c-Jun is also evident in EN hy-
perplastic MECs and tumor cells, but not in WT MGs (Fig-
ures 6Dd–6Dl), suggesting that activation of this AP1
complex is an early event (i.e., present in hyperplastic
MECs) and persists in EN-mediated tumorigenesis.
To determine the c-Jun/Fosl1 status in human SBC, we
stained three SBC cases with c-JUN and FOSL1 anti-
bodies. As shown in Figure 6E, in three of three SBC sam-
ples studied, we detected nuclear staining of FOSL1, and
expression and activation (phosphorylation) of c-JUN,
suggesting that activation of the c-JUN/FOSL1 complex
is indeed associated with human SBC.
Expression of a Dominant-Negative c-Jun Blocks
EN-Mediated Transformation
To determine if AP1 activation is necessary for EN-medi-
ated transformation, we employed the dominant-negative
(DN) c-Jun TAM67, which lacks its transactivation domain,
to block the AP1 activity (Ludes-Meyers et al., 2001) in sev-
eral different systems. Coexpressionof DNc-Jun inEN-3T3
cells blocked EN-mediated transformation both morpho-
logically and molecularly (Figures 7A–7D). Ectopic expres-
sion of EN in the murine EpH4 cells and human MCF10A
cells led to larger spheroids in 3D Matrigel cultures, which
was reverted by coexpression of DN c-Jun (Figures 7E
and 7F). We have shown previously that EN-transduced
EpH4 (EN-EpH4) cells formed tumors upon subcutaneous
injection in immunodeficient mice (Tognon et al., 2002).
Wenowshow that expression of DNc-Jun inEN-EpH4cells
significantly reduces their tumorigenic properties in vivo
(Figures 7G and 7H). We compared microarray expression
profiles between EN-EpH4 tumors and DN c-Jun/EN-EpH4
tumors by GSEA. As expected, many gene sets enriched in
sorted EN tumor cells (compared to unsorted EN tumors)
are downregulated in DN c-Jun/EN-EpH4 tumors (Table
S7). Importantly, one of them is ‘‘JNK_UP,’’ a gene set di-
rectly related to JNK-JUN signaling.
Lastly, we asked whether forced expression of DN c-
Jun in primary EN tumor cells impairs their capacity toCanform new tumors upon transplantation. We developed
a protocol to retrovirally transduce EN tumor cells ex
vivo quickly, sort virally infected Gfp+ cells, and then trans-
plant them into Rag2/ mice immediately. In three inde-
pendent experiments performed, five of five Rag2/
mice transplanted with Gfp+ EN tumor cells transduced
by the control virus (empty vector, LPIG) developed tu-
mors in 23 months, whereas only three of five Rag2/
mice transplanted with the same numbers of Gfp+, DN
c-Jun-transduced EN tumor cells developed tumors
within the same time window. In one tumor derived from
DN c-Jun-transduced EN tumor cells, we detected three
distinct populations of tumor cells expressing high, me-
dium, and low levels of Gfp (Figure 7I). Intriguingly, the
Gfphi population was significantly smaller than the other
two. In contrast, the majority of tumor cells in the control
(LPIG) tumor were Gfp+ cells expressing high levels of
Gfp. We individually sorted these distinct populations of
Gfp+ cells and confirmed they were all derived from virally
transduced cells (Figure 7J). We then quantitated DN c-
Jun expression levels and compared these to virally trans-
duced cells before transplantation (i.e., input). Consistent
with their Gfp expression levels, the Gfphi, Gfpmid, and
Gfplow cells in the DN c-Jun-transduced tumor also ex-
pressed high, medium, and low levels of DN c-Jun, re-
spectively. In addition, even the Gfphi tumor cells ex-
pressed much lower levels of DN c-Jun than those of the
input (Figure 7K). These findings suggest that selection
against EN tumor cells expressing high levels of DN
c-Jun occurs in vivo. Upon staining with antibodies
for stem/progenitor markers CD61 and CD49f, we found
the DN c-Jun-transduced tumors contained fewer
CD61+CD49f+ cells than the control tumors (Figure 7L).
Since CD61+CD49f+ MECs may represent stem/progeni-
tor cells in MGs (Asselin-Labat et al., 2007), we hypothe-
size that forced expression of DN c-Jun in EN tumor cells
may reduce the number of tumor cells capable of initiating
new tumors upon transplantation. Furthermore, in one
Rag2/ mouse transplanted with DN c-Jun-transduced
EN tumor cells, two physically separated tumors devel-
oped. One tumor expressed high levels of Gfp and DN
c-Jun; the other expressed lower levels of Gfp and DN
c-Jun (data not shown). We sorted Gfp+ cells from both
tumors and serially transplanted the same numbers of
sorted cells (ranging from 500 to 5 3 105) into Rag2/
mice. 1.5 months after transplantation, Rag2/ mice
injected with 1 3 105 and 5 3 105 Gfplow (thus also DN
c-Junlow) cells have already developed new tumors,
whereas none of theRag2/ mice transplanted with Gfphi
(thus also DN c-Junhi) cells have developed tumors. This
again suggests that high levels of DN c-Jun expression
in EN tumor cells reduce the number of tumor cells capa-
ble of forming new tumors upon transplantation.(K) Expression levels of DN c-Jun are estimated indirectly by comparing expression levels of the endogenous c-Jun to those of total c-Jun (endog-
enous + DN c-Jun). Expression of the endogenous c-Jun is detected by a PCR primer set located in the region deleted in DN c-Jun. Expression of total
c-Jun is detected by a second primer set located in the common region.
(L) Flow cytometry analysis shows reduced number of CD61+ cells in the DN c-Jun/EN tumor compared to the control tumor. A representative
experiment is shown.cer Cell 12, 542–558, December 2007 ª2007 Elsevier Inc. 553
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Committed Mammary Progenitors as Cells
of Origin for Breast Cancer
A central question in cancer biology is the cellular origin of
cancers. Do cancers originate from normal stem cells that
lose normal growth control, or do they initiate from progen-
itors or more differentiated cells after acquisition of stem
cell attributes through mutation(s) (Lobo et al., 2007)? Cur-
rent views are derived largely from studies of leukemias in
the hematopoietic system. Since hematopoietic stem cells
(HSCs) are endowed with self-renewal, it has been argued
that transformation of HSCs provides a simple means to
generate leukemic cells. Paradoxically, cellular pheno-
types in diverse leukemias mirror those of progenitors,
rather than HSCs (Lobo et al., 2007). In fact, evidence in
both patients and mouse models favors a progenitor cell
origin for many leukemias (e.g., see Jamieson et al.,
2004; Krivtsov et al., 2006).
Similarly, although MaSCs are often proposed as cells
of origin for breast tumors, cellular phenotypes of human
breast cancer are not easily reconciled with this view.
For instance, since MaSCs can give rise to both luminal
and myoepithelial cells, one would expect to see mixed
cell types in breast cancer if MaSCs represent the pre-
dominant cellular origin, yet most human breast tumors
exhibit phenotypes of luminal epithelial cells (Sorlie
et al., 2001). This suggests that more differentiated cells
in MGs may serve as cells of origin for breast cancer. How-
ever, the existence of such committed progenitors in nor-
mal MGs remains to be directly demonstrated. Likewise,
direct evidence is also lacking to show such cells as tar-
gets of transformation leading to breast cancer.
The cellular origin of human breast cancer is difficult to
establish. Murine models, therefore, represent a tractable
alternative for analysis. Previous studies using murine
models have proposed both MaSCs and more differenti-
ated cells, including mammary progenitors, as targets of
breast cancer (Li and Rosen, 2005). Moreover, in murine
models created by overexpression of oncogenes driven
by the same promoter (e.g., MMTV), different oncogenes
(e.g., Wnt1/b-catenin versus Neu or H-Ras or PyMT) ap-
pear to preferentially transform distinct populations of
MECs. However, due to use of exogenous promoters
(thus oncogenes often expressed at nonphysiological
levels), and in the absence of genetic marking and thor-
ough characterization of tumor cell types, these models
cannot definitively assign target cells within the normal
MEC developmental hierarchy.
In WCEN mice, EN is under the transcriptional control
of the endogenous Etv6 promoter and therefore should
be expressed at a physiological level. Since mammary
tumors develop in nulliparous WCEN females at 100%
penetrance and transient Wap+ cells are the only cells in
which EN expression is activated, this unique combination
and the genetic marking experiment described above
provide direct evidence to support committed mammary
progenitors (within the transient Wap+ cells) as targets
of EN.554 Cancer Cell 12, 542–558, December 2007 ª2007 Elsevier IPrevious studies using genetic marking have identified
a population of multipotent MECs (termed parity-induced
MECs, or PI-MECs) that originate from Wap-Cre-express-
ing differentiating cells during the first pregnancy/lactating
cycle, survive through postlactational remodeling, and
persist throughout the remainder of life (Boulanger et al.,
2005; Henry et al., 2004; Wagner et al., 2002; Wagner
and Smith, 2005). Recently, a population of alveolar pro-
genitor cells, similar to PI-MECs, was identified in nullipa-
rous mouse MGs (Booth et al., 2007). These cells repre-
sent lobule-restricted multipotent progenitors capable of
proliferation and differentiation to both luminal and myoe-
pithelial cells upon transplantation. Apparently, these pro-
genitor cells are targets of EN in WCEN virgin females, as
described in this study.
Our study also supports the existence of an epithelial
cell hierarchy in both normal MGs and in mammary tu-
mors. We have described at least two types of committed
alveolar progenitors in the transient population of Wap+
MECs in nulliparous MGs: the bipotent alveolar progeni-
tors as targets of type 1 tumors and the lineage-commit-
ted CD61+ luminal alveolar progenitors as targets of type
2 tumors. However, we cannot exclude the possibility
that type 2 tumors are also derived from bipotent progen-
itors that are blocked in differentiation and only give rise to
CD61+ immature luminal cells. We favor lineage-commit-
ted CD61+ luminal progenitors, rather than bipotent pro-
genitors, as their target cells. In support of this conclusion,
knockout of Gata3 in MGs led to an expansion of CD61+
luminal progenitors and a concomitant block in differenti-
ation (Asselin-Labat et al., 2007), suggesting the existence
of such luminal-restricted progenitors in the normal MEC
hierarchy. In some type 1 EN tumors, we observed regions
with extensive K5+K14+p63+ basal epithelial cells (type
1a), and regions with K8+K14+K5 immature luminal epi-
thelial cells surrounded by K5+K14+p63+ basal/myoepi-
thelial cells (type 1b). This can be best explained by the ex-
istence of an epithelial cell hierarchy in EN tumors. The
committed bipotent alveolar progenitors are transformed
by EN and become oncogenic bipotent progenitors, which
give rise to abnormal luminal-restricted progenitors and
basal/myoepithelial-committed progenitors. In most
cases, these progenitors differentiate into well-differenti-
ated type 1 EN bipotent tumors. Occasionally, either un-
der the influence of the microenvironment, or after acquir-
ing additional mutations, some of the abnormal luminal or
basal/myoepithelial-committed progenitors become fur-
ther transformed and give rise to clones of immature lumi-
nal or basal epithelial cells (due to block in differentiation),
respectively (Figure 8).
K14 is a type II keratin that pairs with the type I keratin
K5 to form heterodimers in basal cells of stratified epithe-
lia. Thus, both K5 and K14 have been considered as basal
cell markers and have been used to distinguish basal/my-
oepithelial cells from K8+ luminal epithelial cells. However,
in this study, we show that K14 also stains a subset of
K8+ luminal epithelial cells, in addition to K5+ basal/myoe-
pithelial cells (Figure 4A and Figures S2A and S7). In fact,
these K14+K8+ luminal cells represent blocked CD61+nc.
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ETV6-NTRK3 Transforms Mammary Progenitors via AP1Figure 8. TheMammary Epithelial Cell Hierarchy in Normal Mammary Glands and inMammary Tumors fromWap-Cre;EN Females
Proposed target cells of EN inWCEN females are indicated (red circles). Red arrows indicate that EN-initiated tumorigenesis (both tumor initiation and
progression) is mediated through AP1.luminal progenitors in EN tumors. Of note, in normal MGs,
a population of K14+K8+ (Figure 4B, this study) or
K14+K18+ luminal cells is also detected (Shackleton
et al., 2006). In addition, our microarray analysis of murine
breast cancer models also shows that the K14 gene clus-
ter is distinct from the K5 basal gene cluster (Figure 4C;
also Herschkowitz et al., 2007). Thus, K14 is distinct
from K5 as a marker, and a combination of both markers
together with other markers (e.g., p63, SMA, K8) can be
used to define subpopulations of cells in murine mammary
tumors.
Although we show that EN transforms committed alve-
olar progenitors, we do not dismiss the possibility that
EN may also transform MaSCs. Interestingly, as we de-
scribed above, due to the leaky expression of the EN allele
(without Cre-mediated excision of the ‘‘stopper,’’ thus
independent of the Wap promoter), a small number of
EN-only heterozygous mice develop mammary tumors
at advanced ages. Most of these tumors fall within one
of the four subtypes described above in WCEN females
(Figure S7), suggesting that target cells of EN in these
two types of mice are probably similar. However, under
this genetic setting, one cannot be certain if bipotent
tumors with type 1 features are derived from committed
bipotent progenitors (similar to WCEN) or from MaSCs,
since they probably give rise to tumors with a similar ap-
pearance. In addition to tumors with features of these
four subtypes, we also observed tumors either containing
extensively K5+ basal cells, or containing mainly K8+ (butCancK14) luminal cells (Figure S7). This is most likely due to
the long latency of tumors that develop in EN-only mice
(>1 year compared to several months for WCEN females).
More differentiated, single lineage-committed cells may
be transformed by EN after they accumulate additional
mutations over an extended time period.
Transformation by EN Oncoprotein Is Mediated
through the AP1 Complex
The AP1 transcriptional complex is composed of heterodi-
meric Jun/Fos family proteins (Eferl and Wagner, 2003).
The AP1 pathway integrates multiple growth signals at
the transcriptional level and regulates several cellular pro-
cesses (Shen et al., 2007). In normal MGs, previous stud-
ies have shown that AP1 is a pivotal regulator of postnatal
MG growth and development (Shen et al., 2006). In human
breast cancer, c-JUN activation is associated with prolif-
eration and angiogenesis in invasive breast cancer (Vleu-
gel et al., 2006). Overexpression of the DN c-Jun in breast
cancer cells induces a G1 cell cycle block and inhibits their
growth both in vitro and in vivo (Liu et al., 2002). Fosl1
(Fra1) regulates proliferation and invasiveness of breast
cancer cells (Belguise et al., 2005; Milde-Langosch
et al., 2004). Overexpression of FOSL1 (FRA-I) protein
has been observed in both hyperplastic and neoplastic
human breast disorders (Chiappetta et al., 2007). In addi-
tion, Fosl1 was also used as an effective target for a DNA
vaccine to protect mice against breast cancer (Luo et al.,
2003).er Cell 12, 542–558, December 2007 ª2007 Elsevier Inc. 555
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ETV6-NTRK3 Transforms Mammary Progenitors via AP1Our findings demonstrate that EN expression leads to
upregulation and activation of the c-Jun/Fosl1 AP1 com-
plex. Several AP1 target genes are upregulated in both
EN-3T3 cells and EN tumor cells (Figures 5A and 5B and
Figures S6A and S6B), including HBEGF and possibly
CCND1 (cyclin D1), which stimulate proliferation. Cyclin
D1 is the major positive regulator of cell cycle progression
induced by AP1 (Bakiri et al., 2000). Although we did not
observe increased levels of cyclin D1 in sorted tumor cells
directly compared to unsorted tumors (possibly due to its
expression in stromal cells), we observed its upregulation
in EN-3T3 cells both by microarray and western blot (Fig-
ures 2D and 5B). We demonstrated its upregulation during
tumor progression (Figure 5C). We also detected high
levels of cyclin D1/2 expression in EN tumors by western
blot (Figure 2D). Intriguingly, our microarray analysis shows
that several AP1 target genes known to promote angiogen-
esis and invasiveness, including PLAUR, PLAU, CD44,
CTSL (cathepsin L), MMP3 (matrix metallopeptidase 3),
and TPM3 (tropomyosin 3) are upregulated in both EN-
3T3 cells and EN hyperplastic MECs (Figures 5B and 5C),
suggesting that an EN/AP1-induced invasiveness program
may be established early in EN-mediated transformation.
This observation may partially account for the short latency
and aggressiveness of EN tumors in mice, and the appear-
ance of SBC in children as young as 3 years of age (Euhus
et al., 2002).
Together with previous observations in human breast
cancer cells, our study supports critical roles of AP1 in
breast tumorigenesis and invasiveness. Further focus on
this transcriptional complex as a target in human breast
cancer is warranted.
Modeling Chromosomal Rearrangements in
Human Epithelial Tumors Can Provide Insights
into Their Pathogenesis and Therapy
The breast cancer model described here is based on the
t(12;15)(p13;q25) translocation in human cancer. Our data
demonstrate that the translocation-generated EN fusion
oncoprotein is sufficient to initiate mammary tumorigene-
sis. This complements genetic evidence in humans sug-
gesting that this translocation is the primary event in the
disorder (Tognon et al., 2002). In our model, EN is induced
only in a very small number of cells in mammary tissues
and the tumor cells emerge within the environment of nor-
mal cells, thus closely mimicking human disease initiated
by somatic mutation. The recent findings of recurrent gene
fusions in prostate cancer and lung cancer suggest that
balanced, disease-specific chromosomal rearrangements
in epithelial cancers may be more common and important
than previously believed (Meyerson, 2007; Tomlins et al.,
2005). As demonstrated in hematopoietic malignancies,
study of gene rearrangements has contributed immeasur-
ably to an understanding of both normal blood cell devel-
opment and malignancy. In addition, study of gene fusions
with kinase activities has revolutionized targeted therapies
for cancer (e.g., imatinib for BCR-ABL fusion). We hope
that the success in modeling an infrequent translocation
seen in human epithelial cancer described here will inspire556 Cancer Cell 12, 542–558, December 2007 ª2007 Elsevier Ithe generation of sophisticated models of other chromo-
somal arrangements that may occur more commonly in
other epithelial tumors. Such engineered mice permit ex-
perimental access to the earliest target cells and steps
in the transformation process and may serve as effective
models for preclinical testing.
EXPERIMENTAL PROCEDURES
Mice
Etv6-NTRK3 conditional knockin mice were generated by gene target-
ing (details are provided in the Supplemental Experimental Proce-
dures). Wap-Cre, MMTV-Cre, and Wap-rtTA-Cre transgenic mice
were acquired from the MMHCC repository at NCI-Frederick. Rosa-
Stop-lacZ reporter mice and Rag2/ immunodeficient mice are main-
tained in our mouse colony. The Rosa-Stop-Luc reporter was kindly
provided by Dr. William G. Kaelin, Jr. All studies involving mice were
approved by the Children’s Hospital Boston Institutional Animal Care
and Use Committee and performed in accordance with the relevant
protocol.
Human SBC Samples
The SBC cases were accrued from Pathology departments at Chil-
dren’s and Women’s Health Centre of British Columbia, Instituto de
Patologia e Imunologia Molecular da Universidade do Porto, and Bur-
naby General Hospital, Burnaby, Canada. Informed consent was ob-
tained for all patient samples used in this study, and ethics approval
was received from the Research Ethic Board (REB) at the University
of British Columbia.
Pathology, Immunostaining, lacZ Staining,
and Flow Cytometry
Standard protocols were followed. Detailed procedures are provided
in the Supplemental Experimental Procedures.
Biochemical and Cellular Assays
Standard protocols were followed. Details about EMSAs, western blot,
immunoprecipitation studies, and soft agar assays are provided in the
Supplemental Experimental Procedures.
Microarray Data Collection and Analysis
Microarray expression profiles were collected using Affymetrix or Agi-
lent chips and analyzed using dChip (Li and Wong, 2001) and GSEA
(Subramanian et al., 2005) as described. Details are provided in the
Supplemental Experimental Procedures. All microarray data have
been deposited in NCBI’s Gene Expression Omnibus (GEO; http://
www.ncbi.nlm.nih.gov/geo/) with GEO Series accession numbers
GSE9355 (EN tumors using Affymetrix chips), GSE9354 (3T3 cells),
GSE9353 (EpH4-derived tumors), and GSE9343 (selected EN tumors
using Agilent chips).
Supplemental Data
The Supplemental Data include Supplemental Experimental Proce-
dures, seven supplemental figures, and eight supplemental tables and
can be found with this article online at http://www.cancercell.org/cgi/
content/full/12/6/542/DC1/.
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